BUZZ-Drugmaker Incyte falls after downbeat annual revenue forecast

Reuters02-10 21:31
BUZZ-Drugmaker Incyte falls after downbeat annual revenue forecast

** Drugmaker Incyte's INCY.O shares fall 5% to $103.62 premarket after weak 2026 revenue forecast

** Forecasts 2026 revenue between $4.77 bln and $4.94 bln, below estimates of $5.52 bln - LSEG-compiled data

** Co flags key growth driver Opzelura will underperform, raising concerns about ability to offset looming patent losses on top-seller Jakafi

** INCY reports Q4 adj. EPS of $1.80 vs analysts' average estimate of $1.93 - LSEG compiled data

** Co's product expenses grow faster than product revenue in Q4

** INCY's R&D expenses increase 37% year-on-year

** Co misses profit estimates for the first time in four quarters - LSEG data

** Q4 revenue, however, beats analysts' estimates on stronger demand for blood-disease drug Jakafi

** INCY stock gained 43% in 2025

(Reporting by Utkarsh Tushar Hathi)

((utkarshtushar.hathi@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment